NCT06491550 - A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 as Well as the Impact of AZD4144 on the Pharmacokinetics of Rosuvastatin and Furosemide in Healthy Participants | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 15, 2024

Primary Completion Date

June 11, 2025

Study Completion Date

June 11, 2025

Conditions

Healthy Participants

Interventions

DRUG

AZD4144- Part A

Part A: Participants will be administered a single dose of AZD4144 on Day 1 via Intravenous (IV) infusion.

DRUG

Placebo- Part A

Part A: Participants will be administered a single dose of placebo on Day 1 via IV infusion.

DRUG

AZD4144- Part B

"Part B: Participants will be administered a single dose of AZD4144 on Day 1 and Day 12 via IV infusion.~Participants will be administered multiple doses of AZD4144 from Day 4 to Day 11 via IV infusion."

DRUG

Placebo- Part B

Part B: Participants will be administered a single dose of placebo on Day 1 and Day 12via IV infusion. Participants will be administered multiple doses of placebo from Day 4 to Day 11 via IV infusion.

DRUG

Rosuvastatin and Furosemide- Part C

Participants will be administered a single oral dose of 10 mg Rosuvastatin and 1 mg Furosemide.

DRUG

Rosuvastatin, Furosemide, and AZD4144 Part C

Participants will be administered a single oral dose of 10 mg Rosuvastatin, 1 mg Furosemide and a single dose of AZD4144 via IV infusion.

Trial Locations (2)

21225

Research Site, Brooklyn

91206

Research Site, Glendale